Imatinib Stada (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, KIT and PDGFRA tyrosine kinases, locking them in an inactive state. This blocks downstream signaling pathways required for uncontrolled proliferation, thereby inducing apoptosis or growth arrest of the malignant cells.

The exact dose of Imatinib Stada is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant therapies. Dosing regimens are established in clinical guidelines and adjusted as needed during treatment.

Safety data for Imatinib Stada in pregnancy and lactation are limited. The drug may pose risks to the fetus and is generally not recommended for use by pregnant or nursing women unless the potential benefit justifies the risk. Women of child‑bearing potential should use effective contraception during therapy.

To place an order, submit an enquiry on the Imatinib Stada product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard of care for CML and GIST. Newer agents such as dasatinib, nilotinib or ponatinib may offer activity against specific resistance mutations, but Imatinib retains a well‑characterised safety profile and is often preferred as first‑line therapy in many treatment algorithms.

Imatinib Stada tablets should be stored at room temperature, below 25 °C, in the original blister or bottle. Protect the product from moisture, excessive heat and direct sunlight to maintain potency throughout its shelf life.

Imatinib Stada is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the regimen without medical advice.

Serious adverse events include severe neutropenia or other cytopenias, hepatotoxicity, and cardiac dysfunction such as heart failure. Prompt monitoring of blood counts, liver enzymes and cardiac status is essential, and any signs of infection, jaundice or dyspnea should trigger immediate medical evaluation.

Imatinib Stada is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those receiving strong CYP3A4 inducers that could markedly reduce drug exposure.